Treatment Guidance of Functional Dyspepsia for Community Pharmacist
Main Article Content
Abstract
Functional dyspepsia is a common disorder in drug store and an important problem which affects to public health system. Functional dyspepsia is defined as discomfort of upper abdominal region, in the absence of any organic disease by upper gastrointestinal endoscopy. Functional dyspepsia is classified into two types by predominant symptoms, postprandial distress syndrome (PDS) such as postprandial fullness or early satiation and epigastric pain syndrome (EPS). Community pharmacists have responsibility to provide pharmaceutical care for patients with functional dyspepsia. The first step of pharmaceutical care should assess the medical history, symptom severity and investigate alarm symptoms to consider about treatment settings of patients between drug store or referral to hospital. Treatment of functional dyspepsia should provide both pharmacotherapy with lifestyle modification. Pharmacotherapy should be based on predominant symptoms as follows: 1) prokinetic drugs (e.g. itopride, domperidone, metoclopramide and mosapride) are used as first line therapy for PDS. Selection of prokinetic drugs should focus on efficacy and safety of each medication to rational use for individual patient. For example, domperidone should be avoided in patients with cardiovascular diseases; 2) antisecretory drugs (e.g. proton pump inhibitors and histamine-2 receptor antagonists) are used as first line therapy for EPS. Proton pump inhibitors are more effective than histamine-2 receptor antagonists. For other gastrointestinal drugs such as antacid, which neutralized acid, found ineffective for the treatment of functional dyspepsia.
Article Details
In the case that some parts are used by others The author must Confirm that obtaining permission to use some of the original authors. And must attach evidence That the permission has been included
References
Bang CS, Kim JH, BaikGH, et al. Mosapride treatment for functional dyspepsia: a meta-analysis. J Gastroenterol Hepatol 2015; 30: 28-42.
Bytzer P. H2 receptor antagonists and prokinetics in dyspepsia. Gut 2002; 50(suppl IV): iv58-62.
Camilleri M, Stanghellini V. Current management strategies and emerging treatments for functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 187-94.
Chen SY, Wang JY, Zhu CW, et al. A randomized controlled multicenter clinical trial on mosapride in the treatment of functional dyspepsia. Chin. J. Epidemiol 2004; 25: 165–8.
Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008; 68(7); 981-91.
Dite P, Rydlo M, Dockal M, et al. A prokinetic agent with a dual effect – itopride – in the treatment of dysmotility. EMJ Gastroenterol 2014; 3: 42-7.
Enck P, Azpiroz, Boeckxstaens G, et al. Functional dyspepsia. Nat Rev Dis Prim 2017; 3: 1-20.
European Medicines Agency. Restrictions on the use of domperidone-containing medicines. September 2014: EMA/465179/2014.
Ford AC, Luthra P, Tack J, et al. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut 2017; 66: 411-20.
Gupta S, Kapoor V, Gupta BM, et al. Effect of itopride hydrochloride on QT interval in adult healthy volunteers. JK-Practitioner 2005; 12(4): 207-10.
Hallerback BI, Bommelaer G, Bredberg E, wt al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 959-67.
Hiyama T, Yoshihara M, Matsuo K, et al. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007; 22: 304-10.
Holtmann G, Tally NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832-40.
Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012; 18(48): 7371-77.
Hu ML, Rayner CK, Wu KL, et al. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J Gastroenterol 2011; 17: 105-10.
Jaafar MH, Safi SZ, Tan MP, et al. Efficacy of rebamipide in organic and functional dyspepsia: a systematic review and meta-analysis. Dig Dis Sci 2018; 63(5): 1250-60.
Kachintorn U. Epidemiology, approach and management of functional dyspepsia in Thailand. J Gastroenterol Hepatol 2011; 26 suppl 3: 32-34.
Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005; 11(27): 4210-4.
Lee KJ, Kindt S, Tack J. Pathophysiology of functional dyspepsia. Best Pract Res Clin Gastroenterol 2004; 18: 707-16.
Loyd RA, McClellan DA. Update on the evaluation and management of functional dyspepsia. Am Fam Physician 2011; 83:547-52.
Miwa H, Ghoshal UC, Gonlachanvit S, et al. Asian consensus report on functional dyspepsia. J Neurogastroenterol Motil 2012; 18: 150-68.
Moshiree B, Barboza J, Tally N. An update on current pharmacotherapy options for dyspepsia. Expert Opin Pharmacother 2013; 14(13): 1-17.
Namarapuekar D, Rane P. Randomized, double-blind, comparative study to evaluate the efficacy and safety of itopride hydrochloride and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004; 102(12): 735-7.
Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol 2018. Doi: 10.1038/s41395-018-0258-6.
Quigley EMM. Prokinetics in the management of functional gastrointestinal disorders. J Neurogastroenterol Motil 2015; 21: 330-6.
Reimer C. Safety of long term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-54.
Saji S. Itopride in the treatment of dysmotility-like functional dyspepsia: a randomized, placebo-controlled trial. J Dig Endos 2010; 1(4): 171-5.
Seto M, Koga S, Kita R, et al. QT-interval prolongation due to medication found in the preoperative evaluation. J Dent Anesth Pain Med 2017; 17(4): 323-27.
Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterol 2016; 150: 1380-92.
Tally NJ. Functional dyspepsia: new insights into pathogenesis and therapy. Korean J Intern Med 2016; 31: 444-56.
Tally NJ, Ford A. Functional dyspepsia. N Engl J Med 2015; 373: 1853-63.
Tally NJ, Tack J, Gupta R, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomized, double-blind, placebo-controlled trials. Gut 2008; 57: 740-6.
Vanheel H, Farre R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10: 142-9.
Wu KL, Rayner CK, Chuah SK, et al. Effects of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol 2008; 20: 436-40.
Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007; 5: 178-85.
Yamawaki H, Futagami S, Wakabayashi M, et al. Management of functional dyspepsia: state of the art and emerging therapies. Ther Adv Chronic Dis 2018; 9(1): 23-32.
Yang YJ, Bang CS, Baik GH, et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol 2017; 17(1): 83.
Zala AV, Walker MM, Tally NJ. Emerging drugs for functional dyspepsia. Expert Opin Emerging Drugs 2015; 20(2): 1-13.